You are here

Article Text

Article menu
Download PDFPDF
Reminder of important clinical lesson
Case report
Follicular eruption as a cutaneous manifestation in COVID-19
  1. Retno Danarti1,
  2. Aries Budiarso2,
  3. Dionisia Lintang Unggul Rini1 and
  4. Hardyanto Soebono1
  1. 1Department of Dermatology and Venereology, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia
  2. 2Department of Dermatology and Venereology, Setjonegoro District Hospital, Wonosobo, Central Java, Indonesia
  1. Correspondence to Dr Retno Danarti; danarti{at}ugm.ac.id

Abstract

A 50-year-old man presented to our dermatology clinic with itchy skin rash. The rash began 5 days after systemic symptoms appeared such as mild fever and mild dyspnoea. The rashes were a characteristic of follicular eruption, which started on his stomach and spread all over his body. After a thorough evaluation, he was diagnosed with COVID-19 and was started on COVID-19 regimens. Skin lesions disappeared on the ninth day of treatment. Our findings contribute to the growing awareness of dermatological manifestations in patients with COVID-19.

  • dermatology
  • infections
  • skin

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

https://bmj.com/coronavirus/usage

https://doi.org/10.1136/bcr-2020-238182

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors Follicular eruption as a cutaneous manifestation in COVID-19. All persons who meet authorship criteria are listed as authors, and all authors certify that they have participated sufficiently in the work to take public responsibility for the content, including participation in the concept, design, analysis, writing or revision of the manuscript. Furthermore, each author certifies that this material or similar material has not been and will not be submitted to or published in any other publication before its appearance in the BMJ Case Reports. Authorship contributions: Category I. Conception and design of study: RD, HS; acquisition of data: RD, AB; analysis and/or interpretation of data: RD, AB, DLUR. Category II. Drafting the manuscript: RD, DLUR; revising the manuscript critically for important intellectual content: RD, HS, AB, DLUR. Category III. Approval of the version of the manuscript to be published: RD, AB, HLUR, HS.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient consent for publication Obtained.

    • Provenance and peer review Not commissioned; externally peer reviewed.